JAKARTA - PT Phapros Tbk, which is a member of the Holding BUMN Pharmaceuticals, established an export-import cooperation with a South Korean company, Korea Arlico Pharma through the signing of a cooperation agreement in Seoul, South Korea in mid-October. In this collaboration, later Phapros will complete the range of local anesthetic products that Phapros currently has.
“This collaboration in the form of a strategic partnership has always been our effort to strengthen our core business and provide the best health products for the community. The products that will be collaborated are local anesthetic products in the form of gel and spray dosage forms with a total of more than 25,000 units and are ready to launch in early 2024," said Imelda.
Previously, the issuer with the PEHA stock code recorded positive growth in the third quarter of 2022, where net sales grew 14 percent over the same period last year. Sales growth was also followed by net profit which jumped to 49 percent compared to the same period in 2021.
In 2023, Phapros will continue to focus on new product innovation and efficiency, including making commercial excellence, operational excellence, financial excellence and digitalization part of the follow-up strategy from this year. (LM)